Recent advances have highlighted the potential of targeting inflammasome components such as sensor proteins (e.g., NLRP3, AIM2), adaptor proteins (e.g., ASC), caspase-1, and downstream cytokines IL-1β and IL-18—to modulate the immune response against cancer. This evidence concerns the gene AIM2 and cancer.